Brainstorm Cell Therapeutics Files 8-K
Ticker: BCLI · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Brainstorm Cell Therapeutics filed a routine 8-K on June 26, 2024, mostly about financial statements.
AI Summary
On June 26, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely related to financial statements and exhibits, without immediate news of significant operational changes.
Risk Assessment
Risk Level: low — The filing appears to be routine administrative and financial reporting, not indicating any immediate significant risks or opportunities.
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
- June 26, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36641 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Brainstorm Cell Therapeutics Inc.?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate reporting.
When was the earliest event reported in this filing?
The earliest event reported was on June 26, 2024.
In which state is Brainstorm Cell Therapeutics Inc. incorporated?
The company is incorporated in Delaware.
What is the Commission File Number for Brainstorm Cell Therapeutics Inc.?
The Commission File Number is 001-36641.
Does this filing mention any specific new product developments or clinical trial results?
The provided text of the filing does not mention any specific new product developments or clinical trial results; it focuses on financial statements and exhibits.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-06-26 16:01:21
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
Filing Documents
- tm2418335d1_8k.htm (8-K) — 24KB
- tm2418335d1_ex99-1.htm (EX-99.1) — 9KB
- 0001104659-24-075146.txt ( ) — 207KB
- bcli-20240626.xsd (EX-101.SCH) — 3KB
- bcli-20240626_lab.xml (EX-101.LAB) — 33KB
- bcli-20240626_pre.xml (EX-101.PRE) — 22KB
- tm2418335d1_8k_htm.xml (XML) — 4KB
01 Other Items
Item 8.01 Other Items. On June 26, 2024, Brainstorm Cell Therapeutics Inc. (the "Company") issued a press release announcing that it had reached alignment with the U.S. Food and Drug Administration (the "FDA") on the Chemistry, Manufacturing, and Controls ("CMC') aspects of the Company's Phase 3b clinical trial for NurOwn, its investigational therapy for amyotrophic lateral sclerosis ("ALS"). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by the Company on June 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: June 26, 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer